Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement must be observed.


PRESS RELEASE
Cantourage achieves new revenue record: EUR 11.1 million in April 2025
Berlin, May 15, 2025 - Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01, www.cantourage.com), Europe's leading listed medical cannabis company, continues its dynamic growth trajectory. In April 2025, the company generated sales of EUR 11.1 million, the highest monthly figure in its history - and surpassed the previous record from March (EUR 10.7 million) directly in the following month.


Growth stabilized at a high level - demand remains strong
The new sales record demonstrates the unbroken demand for Cantourage products - both in Germany and in dynamically growing international markets such as the UK and Poland. Cantourage is excellently positioned to meet the continuing strong demand with optimized product availability, a stable supply chain and specifically expanded processing capacities in Germany and Portugal.


About Cantourage
Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022, under the ticker symbol “HIGH”.


Presscontacts

Pia Senkel |pia.senkel@tonka-pr.com | +49 (0) 173 3702649

Klaas Geller| klaas.geller@tonka-communications.de | +49 (0) 176 74717519

This announcement does not constitute an offer to the public or a solicitation of anoffer to sell securities to the public, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).